<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ferric gluconate: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ferric gluconate: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ferric gluconate: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8936" href="/d/html/8936.html" rel="external">see "Ferric gluconate: Drug information"</a> and <a class="drug drug_patient" data-topicid="11190" href="/d/html/11190.html" rel="external">see "Ferric gluconate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F170704"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ferrlecit</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866885"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Ferrlecit</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1013799"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Iron Salt, Parenteral</span>;</li>
<li>
<span class="list-set-name">Mineral, Parenteral</span></li></ul></div>
<div class="block dop drugH1Div" id="F170715"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Multiple forms for parenteral iron exist; close attention must be paid to the specific product when ordering and administering</b>; incorrect selection or substitution of one form for another without proper dosage adjustment may result in serious over- or under-dosing; test doses are recommended before starting therapy. <b>Note:</b> Per National Kidney Foundation DOQI Guidelines, initiation of iron therapy, determination of dose, and duration of therapy should be guided by results of iron status tests combined with the Hb level and the dose of the erythropoietin stimulating agent. There is insufficient evidence to recommend IV iron if ferritin level &gt;500 ng/mL. Dosage expressed in mg <b>elemental</b> iron:</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fae5446b-fbd8-4834-b702-0d8bc813a28b">Iron-deficiency anemia, hemodialysis patients, repletion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron-deficiency anemia, hemodialysis patients, repletion:</b> Children ≥6 years and Adolescents: IV: 1.5 mg/kg (0.12 mL/kg) repeated at each of 8 sequential dialysis sessions; maximum dose: 125 mg/dose</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="62300a59-2587-430c-9250-e6ae8a3c13ec">Iron-deficiency anemia, hemodialysis patients, maintenance</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron-deficiency anemia, hemodialysis patients, maintenance: </b>Limited data available: Children ≥6 years and Adolescents &lt;17 years: Initial: 1 mg/kg/dose once weekly during dialysis session. Adjust dose to desired iron indices (reported range: 0.75 to 1.5 mg/kg/dose); maximum dose: 125 mg/dose. Dosing based on a study of 35 iron-replete patients (ages 6 to 16 years) on hemodialysis receiving ferric gluconate as maintenance therapy for iron deficiency anemia. Patients were able to maintain targeted iron indices and tolerated the medication (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15064942']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15064942'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block doa drugH1Div" id="F3958031"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8936" href="/d/html/8936.html" rel="external">see "Ferric gluconate: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note</b>: <b>Route of administration: </b>IV iron replacement is preferred over oral replacement in several clinical situations (eg, poor GI absorption, lack of response to or poor tolerability of oral iron, need for rapid repletion, chronic kidney disease, active inflammatory bowel disease, cancer, chronic or extensive blood loss) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Auerbach.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Auerbach.1'])">Ref</a></span>). <b>Dosage expression: </b>Dose is expressed in mg of elemental iron. <b>Test dose: </b>A test dose typically is not required<b>.</b></p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ea1faddf-83d5-47dd-8983-0f9025bbcc3c">Chemotherapy-associated anemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chemotherapy-associated anemia (off-label use):</b> IV infusion: 125 mg once every week for 6 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18375891']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18375891'])">Ref</a></span>) or for 8 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17296819']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17296819'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3f85ed2c-c898-4cdf-82dc-4290871002cd">Iron-deficiency anemia, hemodialysis patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron-deficiency anemia, hemodialysis patients:</b> IV: 125 mg (elemental iron) per dialysis session. For repletion treatment, most patients may require a cumulative dose of 1,000 mg (elemental iron) over ~8 dialysis sessions.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label dosing (based on limited data):</i> After establishing tolerance of the 125 mg dose (elemental iron), single doses of up to 250 mg (elemental iron) have been reported to be safe and well-tolerated in hemodialysis patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12612989','lexi-content-ref-27236131']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12612989','lexi-content-ref-27236131'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="91f66ee0-0e7b-466b-b7e7-c1da1af47fba">Iron-deficiency anemia, treatment, nonhemodialysis patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron-deficiency anemia, treatment, nonhemodialysis patients (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 125 mg per dose is typically used, but may administer up to 250 mg per dose; repeat doses may be given until total iron requirements are met (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28189173','lexi-content-ref-24114623','lexi-content-ref-25556867']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28189173','lexi-content-ref-24114623','lexi-content-ref-25556867'])">Ref</a></span>). Dosing schedule depends on iron deficit and ease of scheduling. Cumulative doses &gt;1 g generally are not required during a single treatment course unless there is ongoing blood loss (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Auerbach.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Auerbach.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991718"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. The ferric gluconate iron complex is not dialyzable.</p></div>
<div class="block doha drugH1Div" id="F50989041"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F170683"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Percentages reported in adult patients unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (children, adolescents, adults: 13% to 23%), hypotension (children, adolescents, adults: 28% to 29%), tachycardia (children, adolescents, adults: 5% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (children, adolescents: 8%; adults: ≤35%), nausea (children, adolescents: 6%; adults: ≤35%), vomiting (children, adolescents: 9%; adults: ≤35%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Abnormal erythrocytes (11%; changes in color, morphology, or number)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (33%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (13%), headache (children, adolescents, adults: 7% to 19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle cramps (25%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (10%), edema (5%), syncope (6%), thrombosis (children, adolescents: 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperkalemia (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (children, adolescents, adults: 3% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (children, adolescents: 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (7%), fatigue (6%), pain (10%), paresthesia (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Lower limb cramp (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (6%), pharyngitis (children, adolescents: 6%), rhinitis (children, adolescents: 3%), upper respiratory tract infection (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (children, adolescents, adults: 3% to 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute coronary syndrome (Kounis syndrome), acute myocardial infarction, angina pectoris, bradycardia, lower extremity edema, peripheral edema, vasodilation</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Heavy menstrual bleeding, hypervolemia, hypoglycemia, hypokalemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, dyspepsia, eructation, flatulence, melena, rectal disease</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, carcinoma, leukocytosis, lymphadenopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Abscess, sepsis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation, chills, drowsiness, impaired consciousness, malaise, rigors</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arm and/or wrist pain, arthralgia, back pain, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis, corneal deposits (arcus senilis), diplopia, eye redness, eyelid edema, nystagmus disorder, watery eyes</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Deafness</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms, pneumonia, pulmonary edema</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Facial flushing, ischemic heart disease (acute; with or without infarction), phlebitis, shock</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pallor, skin discoloration</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including anaphylaxis and severe hypersensitivity reaction)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Inflammation at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Hypertonia, hypoesthesia, loss of consciousness, nervousness, seizure</p></div>
<div class="block coi drugH1Div" id="F170696"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to ferric gluconate or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Anemias not associated with iron deficiency and where there is evidence of iron overload (eg, hemochromatosis, chronic hemolysis) or iron utilization disorders (eg, sideroblastic anemia, lead anemia); serious hypersensitivity to other parenteral iron products; severe inflammatory diseases of the liver or kidneys.</p></div>
<div class="block war drugH1Div" id="F170680"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension: Clinically significant hypotension may occur; usually resolves within 1 to 2 hours. May augment hemodialysis-induced hypotension.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Serious hypersensitivity reactions, including anaphylactic-type reactions, have occurred (may be life-threatening). May present with shock, clinically significant hypotension, loss of consciousness, or collapse. Avoid rapid administration. Equipment for resuscitation and trained personnel experienced in handling medical emergencies should always be immediately available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Use only in patients with documented iron deficiency; caution with hemoglobinopathies or other refractory anemias as iron overload may occur.</p></div>
<div class="block dosfc drugH1Div" id="F21963724"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Strength of ferric gluconate injection is expressed as elemental iron.</p></div>
<div class="block foc drugH1Div" id="F170691"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ferrlecit: 12.5 mg/mL (5 mL) [contains benzyl alcohol, sucrose]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 12.5 mg/mL (5 mL)</p></div>
<div class="block geq drugH1Div" id="F170676"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323148"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ferrlecit Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg/mL (per mL): $7.63</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Na Ferric Gluc Cplx in Sucrose Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg/mL (per mL): $1.97 - $7.63</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866886"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ferrlecit: 12.5 mg/mL (5 mL) [contains benzyl alcohol, sucrose]</p></div>
<div class="block adip drugH1Div" id="F53566690"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Iron storage may lag behind the appearance of normal red blood cell morphology; use periodic hematologic determination to assess therapy</p></div>
<div class="block admp drugH1Div" id="F52612833"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV infusion: Children and Adolescents: Administer diluted over 1 hour</p></div>
<div class="block adm drugH1Div" id="F170693"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;display:inline">IV: Administer diluted over 1 hour or undiluted (slowly) at a rate of up to 12.5 mg/minute per dialysis session. The 250 mg dose (off-label) has been infused (diluted) over 1 to 2 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12612989','lexi-content-ref-25556867']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12612989','lexi-content-ref-25556867'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F170700"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Do not freeze. Use immediately after dilution in NS.</p></div>
<div class="block usep drugH1Div" id="F53566887"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of iron-deficiency anemia in patients undergoing hemodialysis in conjunction with erythropoietin therapy (FDA approved in ages ≥6 years and adults)</p></div>
<div class="block mst drugH1Div" id="F170728"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ferric gluconate may be confused with ferric carboxymaltose, ferumoxytol</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299320"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F170685"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: May enhance the adverse/toxic effect of Ferric Gluconate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimercaprol: May enhance the nephrotoxic effect of Iron Preparations.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levonadifloxacin: Iron Preparations may decrease the serum concentration of Levonadifloxacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F170697"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Iron transfer to the fetus is regulated by the placenta (BSH [Pavord 2020]; NAS 2020).</p>
<p style="text-indent:0em;margin-top:2em;">There is a risk of adverse maternal reactions (eg, anaphylaxis, hypotension, shock) following use of parenteral iron, which may result in fetal bradycardia, especially during the second and third trimesters. An immediate hypersensitivity reaction has been reported in a pregnant patient (Cuciti 2005). Although the risk is rare, immediate treatment for anaphylactoid and/or hypersensitivity reactions should be available (BSH [Pavord 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Maternal iron requirements increase during pregnancy. Untreated iron deficiency and iron-deficiency anemia (IDA) in pregnant patients are associated with adverse pregnancy outcomes, including low birth weight, preterm birth, and increased perinatal mortality (ACOG 2021; BSH [Pavord 2020]). Maternal iron deficiency is also associated with fatigue, increased risk of postpartum depression, and possibly postpartum hemorrhage (BSH [Pavord 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Oral and parenteral iron are effective at replacing iron stores in pregnant patients (ACOG 2021). Most studies note iron therapy improves maternal hematologic parameters, however, data related to clinical outcomes in the mother and neonate are limited (FIGO 2019; NAS 2020; USPSTF [Siu 2015]). Parenteral iron therapy may be used in pregnant patients who cannot tolerate or respond to oral iron, when iron deficiency occurs later in pregnancy, or when malabsorption is present (ACOG 2021; BSH [Pavord 2020]). However, due to limited safety data in early pregnancy, use of intravenous iron is generally not started until the second or third trimester (ACOG 2021; BSH [Pavord 2020]; FIGO 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Ferric gluconate preparations contain benzyl alcohol; avoid use in pregnant patients due to association with gasping syndrome in premature infants.</p></div>
<div class="block mopp drugH1Div" id="F53566886"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Vital signs and other symptoms of anaphylactoid reactions (during IV infusion and for 30 minutes after infusion or until clinically stable); symptoms of hypotension after infusion; reticulocyte count, serum ferritin, hemoglobin, hematocrit, serum iron concentrations, and transferrin saturation (TSAT)</p></div>
<div class="block rerp drugH1Div" id="F53566456"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Serum iron: All ages: 22 to 184 mcg/dL</p>
<p style="text-indent:-2em;margin-left:2em;">Total iron binding capacity:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: 100 to 400 mcg/dL</p>
<p style="text-indent:-2em;margin-left:4em;">Children, Adolescents, and Adults: 250 to 400 mcg/dL</p>
<p style="text-indent:-2em;margin-left:2em;">Chronic kidney disease (CKD): Targets for iron therapy (KDOQI Guidelines 2007) to maintain Hgb 11 to 12 g/dL:</p>
<p style="text-indent:-2em;margin-left:4em;">Children: Nondialysis CKD, hemodialysis, or peritoneal dialysis: Ferritin: &gt;100 ng/mL and TSAT &gt;20%</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Nondialysis (CKD) or peritoneal dialysis: Ferritin: &gt;100 ng/mL and TSAT &gt;20%</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Ferritin &gt;200 ng/mL and TSAT &gt;20% or CHr (content of hemoglobin in reticulocytes) &gt;29 pg/cell</p></div>
<div class="block pha drugH1Div" id="F170679"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Supplies a source to elemental iron necessary to the function of hemoglobin, myoglobin and specific enzyme systems; allows transport of oxygen via hemoglobin</p></div>
<div class="block phk drugH1Div" id="F170695"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Half-life elimination: Bound iron: 1 hour </p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F855042"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ferrlecit</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ferlixit | Ferrlecit</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Ferrlecit</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Ferlecit</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Ferrlecit</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Ferrlecit</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Ferrlecit</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Globac</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ferlixit</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ferrlecit</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Ferrlecit</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ferrlecit</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ferrlecit</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ferrlecit</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ferrlecit | Nulecit</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Ferrlecit</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-gluconate-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ABIM.1">
<a name="ABIM.1"></a>American Board of Internal Medicine. Laboratory Test Reference Ranges. <i>Lexi-Drugs</i>. UpToDate Lexidrug. Waltham, MA: UpToDate Inc. https://online.lexi.com. Accessed December 11, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34293770">
<a name="34293770"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 233: Anemia in pregnancy. <i>Obstet Gynecol. </i>2021;138(2):e55-e64. doi:10.1097/AOG.0000000000004477<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-gluconate-pediatric-drug-information/abstract-text/34293770/pubmed" id="34293770" target="_blank">34293770</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Auerbach.1">
<a name="Auerbach.1"></a>Auerbach M. Treatment of iron deficiency anemia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29222250">
<a name="29222250"></a>Breymann C, Auerbach M. Iron deficiency in gynecology and obstetrics: clinical implications and management. <i>Hematology Am Soc Hematol Educ Program</i>. 2017;2017(1):152-159. doi:10.1182/asheducation-2017.1.152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-gluconate-pediatric-drug-information/abstract-text/29222250/pubmed" id="29222250" target="_blank">29222250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-gluconate-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16140521">
<a name="16140521"></a>Cuciti C, Mayer DC, Arnette R, Spielman FJ. Anaphylactoid reaction to intravenous sodium ferric gluconate complex during pregnancy. <i>Int J Obstet Anesth</i>. 2005;14(4):362-4. doi:10.1016/j.ijoa.2005.05.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-gluconate-pediatric-drug-information/abstract-text/16140521/pubmed" id="16140521" target="_blank">16140521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28189173">
<a name="28189173"></a>DeLoughery TG. Iron deficiency anemia. <i>Med Clin North Am</i>. 2017;101(2):319-332.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-gluconate-pediatric-drug-information/abstract-text/28189173/pubmed" id="28189173" target="_blank">28189173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10705077">
<a name="10705077"></a>Dorea JG. Iron and copper in human milk. <i>Nutrition</i>. 2000;16(3):209-220. doi:10.1016/s0899-9007(99)00287-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-gluconate-pediatric-drug-information/abstract-text/10705077/pubmed" id="10705077" target="_blank">10705077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21548016">
<a name="21548016"></a>El-Farrash RA, Ismail EA, Nada AS. Cord blood iron profile and breast milk micronutrients in maternal iron deficiency anemia. <i>Pediatr Blood Cancer</i>. 2012;58(2):233-238. doi:10.1002/pbc.23184<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-gluconate-pediatric-drug-information/abstract-text/21548016/pubmed" id="21548016" target="_blank">21548016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9363415">
<a name="9363415"></a>Emmett PM, Rogers IS. Properties of human milk and their relationship with maternal nutrition. <i>Early Hum Dev</i>. 1997;49(suppl):S7-S28. doi:10.1016/s0378-3782(97)00051-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-gluconate-pediatric-drug-information/abstract-text/9363415/pubmed" id="9363415" target="_blank">9363415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ferrlecit.1">
<a name="Ferrlecit.1"></a>Ferrlecit (sodium ferric gluconate complex in sucrose) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FerrlecitCAN.1">
<a name="FerrlecitCAN.1"></a>Ferrlecit (sodium ferric gluconate) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30710364">
<a name="30710364"></a>FIGO Working Group on Good Clinical Practice in Maternal-Fetal Medicine. Good clinical practice advice: iron deficiency anemia in pregnancy. <i>Int J Gynaecol Obstet</i>. 2019;144(3):322-324. doi:10.1002/ijgo.12740<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-gluconate-pediatric-drug-information/abstract-text/30710364/pubmed" id="30710364" target="_blank">30710364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12612989">
<a name="12612989"></a>Folkert VW, Michael B, Agarwal R, et al. Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (&gt; or =250 mg) administration. <i>Am J Kidney Dis</i>. 2003;41(3):651-657.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-gluconate-pediatric-drug-information/abstract-text/12612989/pubmed" id="12612989" target="_blank">12612989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24114623">
<a name="24114623"></a>Gomollón F, Gisbert JP. Current management of iron deficiency anemia in inflammatory bowel diseases: a practical guide. <i>Drugs</i>. 2013;73(16):1761-1770.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-gluconate-pediatric-drug-information/abstract-text/24114623/pubmed" id="24114623" target="_blank">24114623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34514189">
<a name="34514189"></a>Gutiérrez O. Treatment of iron deficiency anemia in CKD and end-stage kidney disease. <i>Kidney Int Rep. </i>2021;6(9):2261-2269. doi:10.1016/j.ekir.2021.05.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-gluconate-pediatric-drug-information/abstract-text/34514189/pubmed" id="34514189" target="_blank">34514189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17296819">
<a name="17296819"></a>Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. <i>Oncologist</i>. 2007;12(2):231-242.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-gluconate-pediatric-drug-information/abstract-text/17296819/pubmed" id="17296819" target="_blank">17296819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-gluconate-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17720528">
<a name="17720528"></a>KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target. <i>Am J Kidney Dis.</i> 2007;50(3):471-530.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-gluconate-pediatric-drug-information/abstract-text/17720528/pubmed" id="17720528" target="_blank">17720528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.2">
<a name="KDIGO.2"></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guidelines for anemia in chronic kidney disease (2012). https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-Anemia-Guideline-English.pdf. Accessed December 11, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.1">
<a name="KDIGO.1"></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guidelines for the evaluation and management of chronic kidney disease. <i>Kidney Inter</i>. 2013;3(suppl):1-150. http://kdigo.org/clinical_practice_guidelines/pdf/KDIGO-Anemia%20GL.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18310187">
<a name="18310187"></a>Kumar A, Rai AK, Basu S, et al. Cord blood and breast milk iron status in maternal anemia. <i>Pediatrics</i>. 2008;121(3):e673-e677. doi:10.1542/peds.2007-1986<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-gluconate-pediatric-drug-information/abstract-text/18310187/pubmed" id="18310187" target="_blank">18310187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NASEM.1">
<a name="NASEM.1"></a>National Academies of Sciences, Engineering, and Medicine. <i>Nutrition During Pregnancy and Lactation: Exploring New Evidence: Proceedings of a Workshop</i>. The National Academies Press; 2020. https://doi.org/10.17226/25841
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDQI.1">
<a name="KDQI.1"></a>National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. <i>Am J Kidney Dis.</i> 2007;50(3):529-530. http://www2.kidney.org/professionals/KDOQI/guidelines_anemiaUP/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27236131">
<a name="27236131"></a>Pandey R, Daloul R, Coyne DW. Iron treatment strategies in dialysis-dependent CKD. <i>Semin Nephrol</i>. 2016;36(2):105-111.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-gluconate-pediatric-drug-information/abstract-text/27236131/pubmed" id="27236131" target="_blank">27236131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31578718">
<a name="31578718"></a>Pavord S, Daru J, Prasannan N, Robinson S, Stanworth S, Girling J; BSH Committee. UK guidelines on the management of iron deficiency in pregnancy. <i>Br J Haematol</i>. 2020;188(6):819-830. doi:10.1111/bjh.16221<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-gluconate-pediatric-drug-information/abstract-text/31578718/pubmed" id="31578718" target="_blank">31578718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18375891">
<a name="18375891"></a>Pedrazzoli P, Farris A, Del Prete S, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. <i>J Clin Oncol</i>. 2008;26(10):1619-1625.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-gluconate-pediatric-drug-information/abstract-text/18375891/pubmed" id="18375891" target="_blank">18375891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25556867">
<a name="25556867"></a>Reed BN, Blair EA, Thudium EM, et al. Effects of an accelerated intravenous iron regimen in hospitalized patients with advanced heart failure and iron deficiency. <i>Pharmacotherapy</i>. 2015;35(1):64-71.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-gluconate-pediatric-drug-information/abstract-text/25556867/pubmed" id="25556867" target="_blank">25556867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20975064">
<a name="20975064"></a>Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. <i>J Clin Oncol</i>. 2010;28(33):4996-5010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-gluconate-pediatric-drug-information/abstract-text/20975064/pubmed" id="20975064" target="_blank">20975064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27699922">
<a name="27699922"></a>Roger SD, Tio M, Park HC, et al. Intravenous iron and erythropoiesis-stimulating agents in haemodialysis: a systematic review and meta-analysis. <i>Nephrology (Carlton)</i>. 2017;22(12):969-976.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-gluconate-pediatric-drug-information/abstract-text/27699922/pubmed" id="27699922" target="_blank">27699922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27321965">
<a name="27321965"></a>Shepshelovich D, Rozen-Zvi B, Avni T, Gafter U, Gafter-Gvili A. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta-analysis. <i>Am J Kidney Dis</i>. 2016;68(5):677-690.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-gluconate-pediatric-drug-information/abstract-text/27321965/pubmed" id="27321965" target="_blank">27321965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344176">
<a name="26344176"></a>Siu AL; U.S. Preventive Services Task Force. Screening for iron deficiency anemia and iron supplementation in pregnant women to improve maternal health and birth outcomes: U.S. Preventive Services Task Force Recommendation Statement. <i>Ann Intern Med</i>. 2015;163(7):529-536. doi:10.7326/M15-1707<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-gluconate-pediatric-drug-information/abstract-text/26344176/pubmed" id="26344176" target="_blank">26344176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15064942">
<a name="15064942"></a>Warady BA, Kausz A, Lerner G, et al. Iron therapy in the pediatric hemodialysis population. <i>Pediatr Nephrol</i>. 2004;19(6):655-661.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-gluconate-pediatric-drug-information/abstract-text/15064942/pubmed" id="15064942" target="_blank">15064942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27583315">
<a name="27583315"></a>World Health Organization (WHO). Guideline: iron supplementation in postpartum women. World Health Organization; 2016.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-gluconate-pediatric-drug-information/abstract-text/27583315/pubmed" id="27583315" target="_blank">27583315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. https://iris.who.int/bitstream/handle/10665/85839/WHO_NMH_NHD_MNM_11.1_eng.pdf?sequence=22. Published 2011. Accessed December 11, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2">
<a name="WHO.2"></a>World Health Organization (WHO). Serum ferritin concentrations for the assessment of iron status in individuals and populations: technical brief. https://iris.who.int/bitstream/handle/10665/337666/9789240008526-eng.pdf?sequence=1. Published 2020. Accessed December 11, 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 13053 Version 216.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
